EMA Panel Backs Lilly's Oral Weight-Loss Pill Foundayo, Opening Second European Market
LLY sits 60% above its 52-week low of $783.845.
Summary
The European Medicines Agency's committee recommended approval of Foundayo, Lilly's oral weight-loss pill, clearing the path for a second oral obesity drug in Europe after Novo Nordisk's Wegovy pill. This follows the FDA's earlier approval of Foundayo noted in the Q2 10-Q, extending the franchise into a major new market. Lilly already trades near a 52-week high on the back of a 48% Q2 revenue surge to $23B driven by Mounjaro and Zepbound, so European clearance adds a fresh revenue leg rather than rescuing a weak story. The EMA recommendation is a committee opinion; final European Commission authorization is the next formal step, and launch timing and pricing in the region will determine how quickly it contributes.
Updates
· Benzinga — Foundayo recommended for both type 2 diabetes and weight management, in film-coated tablets from 0.8 mg to 17.2 mg orforglipron; Lilly shares rose 1.44% to $1,269.60.
At the time of this announcement, LLY was trading at $1,257.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.2T. The 52-week trading range was $783.85 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.